Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Vote in favor of the wide open action that revives your brain and soul! - 2Lift Your Style: Famous Hairdos for Ladies
- 3The most effective method to Execute a Lung-Solid Eating routine After a Cellular breakdown in the lungs Finding
- 4Army commander convicted of Guinea stadium massacre dies in prison
- 5Tatiana Schlossberg, a granddaughter of JFK, is dead at 35 after cancer diagnosis
- Ryan Gosling responds to Deidre Hall's invitation to visit the 'Days of Our Lives' set: 'This is a very enthusiastic yes'
- Zelensky sees win for Ukraine as EU finally reaches funding deal
- Israel Police arrest twenty-one as anti-war protests grow despite broad support for Iran war
- She was moments away from giving birth. The hospital discharged her
- Massachusetts court hears arguments in lawsuit alleging Meta designed apps to be addictive to kids
- I took my shoes off and went for a barefoot hike. I couldn’t believe what happened next
- The most effective method to Engage in Local area Making arrangements for 5G Pinnacle Establishments
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- Hostages as leverage: Iran's secret demand aimed at crippling Israel's agriculture
